Quick Takeaways
- MPM BioVentures 2014, L.P. filed SCHEDULE 13D/A for ITEOS THERAPEUTICS, INC. Common Stock (ITOS).
- Disclosed ownership: 4.7%.
- Date of event: 13 May 2025.
Quoteable Key Fact
"MPM BioVentures 2014, L.P. disclosed 4.7% ownership in ITEOS THERAPEUTICS, INC. Common Stock (ITOS) on 13 May 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 1.6% | 621,312 | 621,312 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P. | 0001609492 |
| MPM BioVentures 2014 (B), L.P. | 0.1% | 39,135 | 39,135 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P | 0001609493 |
| MPM Asset Management Investors BV2014 LLC | 0.1% | 21,385 | 21,385 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC | 0001609495 |
| MPM BIOVENTURES 2018, L.P. | 1% | 392,407 | 392,407 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2018 LLC, the Managing Member of MPM BioVentures 2018 GP LLC, the General Partner of MPM BioVentures 2018, L.P. | 0001729505 |
| MPM BIOVENTURES 2018 (B), L.P. | 0.1% | 19,697 | 19,697 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2018 LLC, Managing Member of MPM BioVentures 2018 GP LLC, the General Partner of MPM BioVentures 2018 (B), L.P | 0001729504 |
| MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 0% | 7,749 | 7,749 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC | 0001734817 |
| UBS Oncology Impact Fund L.P. | 1.8% | 702,311 | 702,311 | 0 | /s/ Ansbert Gadicke | Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P. | 0001691428 |
| MPM BioVentures 2014 GP LLC | 1.7% | 660,447 | 0 | 660,447 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC | 0001765091 |
| MPM BioVentures 2014 LLC | 1.8% | 681,832 | 0 | 681,832 | /s/ Ansbert Gadicke | Managing Director | 0001765021 |
| MPM BioVentures 2018 GP LLC | 1.1% | 412,104 | 0 | 412,104 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2018 LLC, the Managing Member of MPM BioVentures 2018 GP LLC | 0001818701 |
| MPM BioVentures 2018 LLC | 1.1% | 419,853 | 0 | 419,853 | /s/ Ansbert Gadicke | Managing Director | 0001818702 |
| Oncology Impact Fund (Cayman) Management L.P. | 1.8% | 702,311 | 0 | 702,311 | /s/ Ansbert Gadicke | Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P. | 0001721036 |
| MPM BioImpact LLC | 1.8% | 702,311 | 0 | 702,311 | /s/ Ansbert Gadicke | Managing Partner | 0001687078 |
| ANSBERT GADICKE | 4.7% | 1,803,996 | 0 | 1,803,996 | /s/ Ansbert Gadicke | Ansbert Gadicke | 0001134655 |
| LUKE EVNIN | 2.9% | 1,101,685 | 0 | 1,101,685 | /s/ Luke Evnin | Luke Evnin | 0001134657 |
| Todd Foley | 2.9% | 1,101,685 | 0 | 1,101,685 | /s/ Todd Foley | Todd Foley | 0001473930 |